Health Bulletin 28/November/2023

Published On 2023-11-28 11:32 GMT   |   Update On 2023-11-28 11:32 GMT

Here are the top health stories for the day:

MCC releases revised schedule for NEET SS Counselling 2023, Round 1 reporting deadline extended, know Round 2 dates

The Medical Counselling Committee (MCC) has released the revised schedule for the NEET SS counselling process.

As per the revised schedule, the reporting process for Round 1 has been extended up to 30th Nov. 2023. Previously, it was till 24th Nov. 2023.

Round 2 -The registration facility will be available from 5th Dec. 2023 up to 12:00 NOON of 10th Dec. 2023 (as per Server Time). The payment facility will be available from 5th Dec., 2023, up to 03:00 PM of 10th Dec., 2023, as per Server Time. Choice Filling is available from 6th Dec., 2023, up to 11:55 P.M. of 10th Dec. 2023. Choice Locking Facility available from 04:00 P.M of 10th Dec., up to 11:55 P.M of 10th Dec., 2023.

For more details, check out the link given below:

MCC Releases Revised Schedule For NEET SS Counselling 2023, Round 1 Reporting Deadline Extended, Know Round 2 Dates


"Respiratory illness in China due to common viruses": AIIMS Doctor

Amid rising cases of respiratory illness in China, a senior doctor from the All India Institute of Medical Sciences has said that viral infections are common in winter and there is no possibility of another pandemic like Covid yet.

A notable surge has been reported in respiratory illness in children in northern China in recent weeks.

Dr SK Kabra, Head of Department, Mother and Child Block, AIIMS, told ANI, "The reports coming from China now show that there has been a sudden increase in respiratory infections between October and November and they have observed that it is more common in children.

For more details, check out the link given below:

Respiratory Illness In China Due To Common Viruses, Clarifies AIIMS Doctor


From Rs 2.5 Crore pa to Rs 2.5 lakh per annum: Soon, make in India drugs for rare diseases to change medicine spectrum

The Centre has come up with a game-changer special initiative by manufacturing four types of homegrown 'Made in India' drugs for rare diseases for the first time.

The Central Government has prioritised 13 rare diseases and sickle cell disease. The most awaited initiative was taken in July 2022 after discussions held with the academia, pharma industries, organisations and CDSCO department of pharmaceuticals.

For more details, check out the link given below:

From Rs 2.5 Crore Pa To Rs 2.5 Lakh Per Annum: Soon, Make In India Drugs For Rare Diseases To Change Medicine Spectrum


Cannot infringe Apollo's trademark: Bihar doctor tries to run 'New Appolo Hospital', pulled up by high court

The Madras High Court bench recently observed that the trademark "Apollo" was a well-known trademark in the healthcare and pharmaceutical sector and it was entitled to the highest level of protection as the public at large associate the name "Apollo" only with the healthcare group.

With this observation, the Madras HC bench comprising Justice Abdul Quddhose granted relief to the Apollo group, in a trademark infringement lawsuit against a private hospital by a Bihar-based doctor. The Hospital run by the concerned doctor was named "New Appolo Hospital".

For more details, check out the link given below:

Cannot Infringe Apollo's Trademark: Bihar Doctor Tries To Run 'New Appolo Hospital', Pulled Up By High Court

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News